Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month […]
More Stories
US Allows Venezuela to Fund Maduro’s Defense After Court Challenge
By Tom Gantert The United States will ease sanctions on Venezuela to allow its regime to pay legal fees for...
Monsanto Weedkiller Case Could Upend Billions in Compensation
By Troy Myers and Jacob Burg Like countless homeowners, John Durnell of Missouri used a popular herbicide to keep his...
Planned Obsolescence: The Silent Sabotage of the Devices We Depend On
By Stephen Zogopoulos, USNN World News The Illusion of Progress Walk into any electronics store today and you’ll see the...
Shots Fired at White House Correspondents’ Dinner, Trump Evacuated, Suspect Detained
By Emel Akan and Sam Dorman President Donald Trump and First Lady Melania Trump were evacuated from the White House...
US Forces Intercept, Turn Back Iran-Linked Tanker in Arabian Sea
By Ryan Morgan A U.S. Navy helicopter intercepted and turned back toward Iran a sanctioned petrochemical tanker in the Arabian...
Iran Offered Better Deal ‘10 Minutes’ After US Canceled Pakistan Meeting, Trump Says
By Jacki Thrapp The Iranian regime offered the United States a “much better” peace deal within 10 minutes of President...